UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013682
Receipt number R000015622
Scientific Title The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia
Date of disclosure of the study information 2014/04/18
Last modified on 2015/04/14 09:43:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

Acronym

The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

Scientific Title

The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

Scientific Title:Acronym

The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

Region

Japan


Condition

Condition

Type2 diabetes mellitus patients with dyslipidemia

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect on lipid lowering effects and their mechanism of anagliptin in type 2 diabetes mellitus patients with dyslipidemia

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of sitosterol, campesterol and lathosterol

Key secondary outcomes

Change of serum lipids and apolipoproteins


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

anagliptin as a suiny tablet.Taking a dose of 100 to 200 mg twice a day.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Type2 diabetes mellitus patients who accords the terms below.
1.Patients whose LDL-C between 100mg/dL to 160mg/dL with or without taking drugs for dyslipidemia.
2.Patients whose treatment for diabetes mellitus will not change between the trial periods.
3.Written informed consent is obtained from subjects before entry.
4.Patients who is over 20years old.

Key exclusion criteria

1.Patients who accord the contraindication of anagliptin.
2.Patients whose HbA1c over 8.0% before entry.
3.Patients who suffered coronary heart disease in past.
4.Patients whose renal function is declined (Ccr below the 30) or ongoing dialysis.
5.Individuals who are ineligible in the opinion of the physician in charge.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Makoto Kinoshita

Organization

Teikyo university

Division name

Internal Medicine

Zip code


Address

2-11-1 Kaga, Itabashi-Ku, Tokyo 173-8606

TEL

03-3964-1211

Email

makkino@med.teikyo-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mitsunobu Kawamura

Organization

Tokyo Teishin Hospital

Division name

Internal Medicine

Zip code


Address

2-14-23 Fujimi, Chiyoda-ku Tokyo 102-8798

TEL

03-5214-7111

Homepage URL


Email

mk-hakodate@tth-japanpost.jp


Sponsor or person

Institute

Internal Medicine, Teikyo University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 04 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 04 Month 18 Day

Date of IRB


Anticipated trial start date

2014 Year 04 Month 18 Day

Last follow-up date


Date of closure to data entry

2014 Year 12 Month 20 Day

Date trial data considered complete

2014 Year 12 Month 20 Day

Date analysis concluded

2014 Year 12 Month 20 Day


Other

Other related information



Management information

Registered date

2014 Year 04 Month 10 Day

Last modified on

2015 Year 04 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015622


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name